HighPoint Advisor Group’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

HighPoint Advisor Group’s Portfolio NWBO Stock Details NWBO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-19,450	Closed	-$4K	–	362
2018 Q4	$4K	Buy	+19,450	New	+$4K	﹤0.01%	321

Other funds holding NWBO

SAM

Seelaus Asset Management Chatham, New Jersey $142M AUM 48.54% 1-Year Est. Return

WPP

Whalerock Point Partners Providence, Rhode Island $518M AUM 25.26% 1-Year Est. Return

LDB

Lee, Danner & Bass Nashville, Tennessee $1.73B AUM 36.69% 1-Year Est. Return

CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return

MPI

Mairs & Power Inc St Paul, Minnesota $9.79B AUM 20.6% 1-Year Est. Return

HighPoint Advisor Group's NWBO Position: Q1 2019 in Review

HighPoint Advisor Group sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q1 2019, closing a stake of 19,450 shares — an estimated $4K sold.

HighPoint Advisor Group first reported a position in NWBO in Q4 2018 and held it in 1 quarter. The position peaked at $4K in Q4 2018. 5 funds tracked by Wall St. Rank hold NWBO as of Q1 2019.

HighPoint Advisor Group reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q1 2019 after selling out during the quarter.
HighPoint Advisor Group sold 19,450 Northwest Biotherapeutics, Inc. Common stock shares in Q1 2019, an estimated $4K.
HighPoint Advisor Group first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q4 2018 and held it in 1 quarter.
HighPoint Advisor Group's Northwest Biotherapeutics, Inc. Common stock position peaked at $4K in Q4 2018.
5 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q1 2019.

Based on HighPoint Advisor Group's 13F filing for Q1 2019, filed 8 May 2019.